Evidence map›Paper›PMID 35990702›Full record

ArticleNeuro-oncology advances

An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin.

Liat Peretz Zats, Labiba Ahmad, Natania Casden, Meelim J Lee, Vitali Belzer, Orit Adato, Shaked Bar Cohen, Seung-Hyun B Ko, Mariella G Filbin, Ron Unger and 3 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Liat Peretz ZatsDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.
Labiba AhmadDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.
Natania CasdenDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.
Meelim J LeeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.
Vitali BelzerDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.
Orit AdatoFaculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel.
Shaked Bar CohenDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.
Seung-Hyun B KoDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.
Mariella G FilbinDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA.
Ron UngerFaculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.
Rosalind A SegalDepartment of Neurobiology, Harvard Medical School, Boston, MA, USA.
Oded BeharDepartment of Developmental Biology and Cancer Research, Faculty of Medicine, The Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.ORCID https://orcid.org/0000-0001-6913-2827
Hebrew University of Jerusalem · ILMassachusetts Institute of Technology · USBar-Ilan University · ILDana-Farber/Boston Children's Cancer and Blood Disorders Center · USHarvard University · US

Funding

Trans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2016 to 2020
$10.2M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacyU01CA215798 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HAAS, WILHELM, HAIGIS, KEVIN · 2017 to 2021
$3.7M
NCI NIH HHS U01 CA215798NCI NIH HHS U54 CA210180NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

Background: High-grade gliomas (HGG) in children have a devastating prognosis and occur in a remarkable spatiotemporal pattern. Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), typically occur in mid-childhood, while cortical HGGs are more frequent in older children and adults. The mechanisms behind this pattern are not clear. Methods: We used mouse organotypic slice cultures and glial cell cultures to test the impact of the microenvironment on human DIPG cells. Comparing the expression between brainstem and cortical microglia identified differentially expressed secreted proteins. The impact of some of these proteins on DIPGs was tested. Results: DIPGs, pediatric HGGs of brainstem origin, survive and divide more in organotypic slice cultures originating in the brainstem as compared to the cortex. Moreover, brainstem microglia are better able to support tumors of brainstem origin. A comparison between the two microglial populations revealed differentially expressed genes. One such gene, interleukin-33 (IL33), is highly expressed in the pons of young mice and its DIPG receptor is upregulated in this context. Consistent with this observation, the expression levels of IL33 and its receptor, IL1RL1, are higher in DIPG biopsies compared to low-grade cortical gliomas. Furthermore, IL33 can enhance proliferation and clonability of HGGs of brainstem origin, while blocking IL33 in brainstem organotypic slice cultures reduced the proliferation of these tumor cells. Conclusions: Crosstalk between DIPGs and the brainstem microenvironment, in particular microglia, through IL33 and other secreted factors, modulates spatiotemporal patterning of this HGG and could prove to be an important future therapeutic target.

Indexed as

DIPGinterleukin-33microgliapediatric high-grade gliomas

Identifiers

PMID35990702
PMCPMC9389428
OpenAlexW4286491584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.